1. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
- Author
-
Cragun D, Weidner A, Tezak A, Clouse K, and Pal T
- Subjects
- Adolescent, Adult, Ataxia Telangiectasia Mutated Proteins genetics, BRCA1 Protein genetics, BRCA2 Protein genetics, Breast Neoplasms diagnosis, Breast Neoplasms genetics, Checkpoint Kinase 2 genetics, Fanconi Anemia Complementation Group N Protein genetics, Female, Genetic Carrier Screening statistics & numerical data, Genetic Predisposition to Disease, Germ-Line Mutation, Guideline Adherence standards, Guideline Adherence statistics & numerical data, Hereditary Breast and Ovarian Cancer Syndrome diagnosis, Hereditary Breast and Ovarian Cancer Syndrome genetics, Heterozygote, Humans, Medical History Taking, Medical Overuse prevention & control, Medical Overuse statistics & numerical data, Ovariectomy standards, Practice Guidelines as Topic, Practice Patterns, Physicians' standards, Prophylactic Mastectomy standards, Young Adult, Breast Neoplasms prevention & control, Hereditary Breast and Ovarian Cancer Syndrome prevention & control, Ovariectomy statistics & numerical data, Practice Patterns, Physicians' statistics & numerical data, Prophylactic Mastectomy statistics & numerical data
- Abstract
Purpose: Identification of inherited breast cancer may guide cancer risk management. We sought to compare risk management practices across women with inherited breast cancer genes., Methods: Females with a pathogenic/likely pathogenic (P/LP) variant in BRCA1/2, PALB2, CHEK2, and/or ATM were surveyed about cancer risk management. Comparisons were made across genes., Results: The 235 participants with P/LP variants (186 BRCA1/2, 28 PALB2, 15 CHEK2, and 6 ATM) had a median age of 54 and 61% had a prior breast cancer diagnosis. For women with P/LP variants in BRCA1/2, PALB2, and ATM/CHEK2, bilateral mastectomy (BM) rates were 79%, 61%, and 52%, and bilateral oophorectomy (BO) rates were 89%, 30%, and 37%, respectively. Among women with P/LP variants in PALB2 and ATM/CHEK2, 27% of those who had a BO had a family history of ovarian cancer. Contralateral mastectomy rates for women with P/LP variants in PALB2 and ATM/CHEK2 with unilateral breast cancer were 60% and 58%, and BM rates for those without breast cancer were 57% and 29%, respectively., Conclusion: These findings suggest high rates of both contralateral mastectomies among those with unilateral breast cancer and BM among those without a breast cancer diagnosis across women with P/LP variants in high and moderate penetrance breast cancer genes. BO was also often utilized for risk reduction across these women. These findings suggest potential overtreatment through risk-reducing surgery, and highlight the importance of promoting guideline-adherent, risk-appropriate care.
- Published
- 2020
- Full Text
- View/download PDF